Aamir Malik, Pfizer
February 8, 2022 01:37 PM EST
Deals
Pharma

Al­bert Bourla has some plans for Pfiz­er's huge Covid cash haul. Hint: 'Ac­qui­si­tions are very much in the card­s'

John Carroll

Editor & Founder

To­day was Pfiz­er CEO Al­bert Bourla’s chance to rel­ish the mar­ket suc­cess of its Covid vac­cine and drug and what a fresh flow of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Trump’s sci­ence crack­down hits rare dis­ease re­search: ‘We need to sit down with Elon Musk’

At least sev­en drug­mak­ers say they will par­tic­i­pate in round two of IRA ne­go­ti­a­tions 

Lil­ly joins mol­e­c­u­lar glue field with Mag­net deal worth up to $1.25B

Ex­clu­sive: In­fec­tious dis­ease doc­tors con­sid­er 'mi­ni-ACIP' if RFK erodes CDC vac­cine pan­el

Bridge­Bio on­col­o­gy spin­out to go pub­lic via com­bi­na­tion with SPAC from Cor­morant and Bi­hua Chen

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times